Biotech & Investing Glossary

Understanding the language of drug development is essential for anyone evaluating life science companies. This glossary defines key terms used by regulators, researchers, and investors — from clinical trial phases to financing structures. Each definition is accompanied by a real-world example to ground the concept in practice.

ADC (Antibody‑Drug Conjugate)

A targeted cancer therapy that links a cytotoxic drug to a monoclonal antibody. The antibody homes in on a specific protein on cancer cells, delivering the toxin directly while sparing healthy tissue. This “biological missile” approach can improve the therapeutic window compared to conventional chemotherapy.

Example: Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) targets HER2‑positive breast, gastric and lung cancers, achieving tumor shrinkage in heavily pretreated patients.

Adverse Event (AE)

Any untoward medical occurrence in a patient during a clinical trial, whether or not it is considered related to the investigational product. AEs are graded by severity from 1 (mild) to 5 (death) and must be reported to regulators. A favorable safety profile means few high‑grade or treatment‑related AEs.

Example: In the phase III EMPEROR‑Reduced trial, Jardiance was associated with fewer serious adverse events than placebo in heart failure patients.

Biologic (Biopharmaceutical)

A large‑molecule drug produced in living systems, such as mammalian cells, yeast, or bacteria. Biologics include monoclonal antibodies, vaccines, gene therapies, and recombinant proteins. Their complexity makes them more expensive to manufacture and harder to copy than small‑molecule drugs, leading to a higher barrier for biosimilar competition.

Example: AbbVie’s Humira (adalimumab) is a monoclonal antibody that dominated the immunology market for two decades before facing biosimilars in 2023.

Biomarker

A measurable biological indicator that can signal a normal or pathogenic process, or a pharmacological response to a therapeutic intervention. Biomarkers are used in clinical trials to select patients (enrichment), monitor disease progression, or predict treatment benefit. They are often the basis for companion diagnostics.

Example: Elevated TROP‑2 expression is used as a biomarker to select patients for Gilead’s Trodelvy in triple‑negative breast cancer.

Biosimilar

A follow‑on version of an originator biologic that is highly similar in structure, function, and clinical profile, but not identical. In the U.S., biosimilars must demonstrate no clinically meaningful differences from the reference product and typically launch at a 15–35% discount to capture market share.

Example: Amgen’s Amjevita was the first biosimilar to Humira approved in the U.S., launching in January 2023.

Breakthrough Therapy Designation

An FDA status granted to a drug intended to treat a serious condition when preliminary clinical evidence indicates substantial improvement over existing therapies on a clinically significant endpoint. It confers intensive FDA guidance, senior management involvement, and rolling review of the marketing application, which can shorten the review time.

Example: Bluebird Bio’s Zynteglo (betibeglogene autotemcel) for beta‑thalassemia received Breakthrough Therapy designation before its conditional approval in Europe.

Clinical Endpoint

A precisely defined measure used to determine whether a treatment has a clinical effect. Primary endpoints are the main outcomes used to judge efficacy (e.g., overall survival, progression‑free survival), while secondary endpoints provide supportive information. The choice of endpoint directly influences trial size, duration, and likelihood of regulatory success.

Example: The KEYNOTE‑775 trial for Keytruda in endometrial cancer used progression‑free survival as its primary endpoint, showing a statistically significant improvement over chemotherapy.

Clinical Trial Phase I, II, III

Clinical development proceeds through sequential phases. Phase I enrolls a small number of healthy volunteers or patients to assess safety, tolerability, and pharmacokinetics. Phase II explores efficacy signals at various doses in a larger patient group. Phase III confirms efficacy and monitors safety in a broad, controlled population and is usually the basis for regulatory approval. The failure rate rises sharply between each phase.

Example: Moderna’s mRNA‑1273 COVID‑19 vaccine advanced from a phase I safety study (45 adults) to a phase III trial of 30,000 participants in less than 10 months during the pandemic.

Dilution

The reduction in existing shareholders’ ownership percentage that occurs when a company issues new shares, typically through a follow‑on offering, convertible debt conversion, or exercise of warrants. Biotech companies without revenue often rely on equity financing, making dilution a key consideration for investors. Management’s ability to raise capital at favorable terms affects long‑term shareholder value.

Example: In 2022, many early‑stage biotechs raised cash through at‑the‑market (ATM) programs, diluting existing holders by 10–20% to extend their cash runway.

EMA (European Medicines Agency)

The regulatory agency of the European Union responsible for the scientific evaluation of medicines for human and veterinary use. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issues opinions that are then ratified by the European Commission, resulting in a centralized marketing authorization valid in all EU member states.

Example: Novo Nordisk’s Wegovy (semaglutide) received EMA approval in 2022 for weight management, complementing its earlier U.S. approval.

Fast Track Designation

An FDA program that expedites the review of drugs intended to treat serious conditions and that fill an unmet medical need. Benefits include more frequent meetings with the FDA, eligibility for Accelerated Approval and Priority Review, and the possibility of submitting sections of a marketing application on a rolling basis.

Example: Vertex Pharmaceuticals’ Trikafta was granted Fast Track status for cystic fibrosis, contributing to a review and approval in under five months for its triple‑combination therapy.

FDA (U.S. Food and Drug Administration)

The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biologics, and medical devices in the United States. The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) oversee the approval process, from Investigational New Drug (IND) applications to post‑market surveillance.

Example: The FDA approved Biogen’s Leqembi (lecanemab) as a traditional Alzheimer’s treatment in 2023 after an accelerated approval pathway in early 2023.

Gene Therapy

A technique that introduces, removes, or alters genetic material inside a patient’s cells to treat or cure a disease. Vectors (often adeno‑associated viruses, AAVs) deliver the therapeutic gene. Durability of effect is a key advantage, but manufacturing complexity and potential immune responses remain challenges. Approved gene therapies have commanded multi‑million‑dollar price tags.

Example: Novartis’ Zolgensma (onasemnogene abeparvovec) treats spinal muscular atrophy with a single intravenous infusion and was priced at $2.1 million per patient at launch.

IND (Investigational New Drug Application)

A submission to the FDA before a company can begin human clinical trials in the United States. The IND must contain manufacturing information, results from preclinical animal studies demonstrating safety, and a clinical protocol. If the FDA does not issue a clinical hold within 30 days, the trial may proceed.

Example: BioNTech filed an IND in 2022 for its mRNA‑based cancer vaccine candidate BNT111, allowing a multi‑center phase II trial to open in the U.S.

Market Capitalization (Market Cap)

The total value of a company’s outstanding shares, calculated by multiplying the share price by the number of shares outstanding. Biotech market caps often swing dramatically on clinical data readouts, regulatory decisions, or partnership announcements. Micro‑cap and small‑cap biotechs typically have higher risk‑reward profiles than large‑cap pharma.

Example: After positive phase II data for danuglipron, Pfizer’s market cap increased by roughly $6 billion in a single day, reflecting the perceived value of the oral GLP‑1 program.

Monoclonal Antibody (mAb)

A laboratory‑produced molecule that can mimic the immune system’s ability to fight off harmful pathogens such as viruses or cancer cells. mAbs are engineered to bind to a single antigen with high specificity. Naming conventions end with the suffix “‑mab” (e.g., adalimumab, trastuzumab).

Example: Regeneron’s Dupixent (dupilumab) is a fully human monoclonal antibody that blocks IL‑4 and IL‑13 signaling, approved for multiple allergic and inflammatory conditions.

mRNA (Messenger RNA) Therapeutics

A platform technology in which synthetic messenger RNA instructs cells to produce a therapeutic protein. This approach can be used for vaccines (infectious diseases, cancer) and protein replacement therapies. The rapid adaptability of mRNA allowed COVID‑19 vaccines to be designed within days of the SARS‑CoV‑2 sequence being published.

Example: Moderna’s mRNA‑4157 cancer vaccine, combined with Keytruda, reduced the risk of recurrence or death by 44% in a phase II trial for melanoma patients, according to data presented at ASCO 2023.

NDA / BLA (New Drug Application / Biologics License Application)

The formal request submitted to the FDA for permission to market a new drug product in the United States. An NDA is required for small‑molecule drugs, while a BLA is used for biologics. Both must present comprehensive data on chemistry, manufacturing, controls, safety, and efficacy, often totaling hundreds of thousands of pages.

Example: Argenx filed a BLA for efgartigimod in 2021, supported by the phase III ADAPT trial, and received FDA approval as Vyvgart for generalized myasthenia gravis in December 2021.

Orphan Drug Designation

An FDA status that provides incentives for the development of drugs for rare diseases (affecting fewer than 200,000 people in the U.S.). Benefits include seven years of market exclusivity upon approval, tax credits for clinical trial costs, and waiver of certain FDA fees. The designation can be requested before the first IND and does not require proof of superiority.

Example: Sarepta Therapeutics secured orphan drug status for Elevidys, a gene therapy for Duchenne muscular dystrophy, which was later granted accelerated approval.

Patent Cliff

The period when a blockbuster drug’s key patents expire, opening the door for generic or biosimilar competition and causing a sharp decline in sales. Pharmaceutical companies often build next‑generation products, pursue new indications, or engage in M&A to offset the revenue loss.

Example: Bristol Myers Squibb faces the loss of exclusivity for Eliquis (apixaban) in 2027–2028, which could expose over $10 billion in annual sales to generic rivals.

PDUFA Date (Prescription Drug User Fee Act Date)

The target decision date by which the FDA is expected to complete its review of an NDA or BLA. The review clock starts at the time of submission and typically runs six months for Priority Review and ten months for Standard Review. The PDUFA date is a key binary event for biotech investors.

Example: Madrigal Pharmaceuticals had a PDUFA date of 14 March 2024 for resmetirom, a potential first‑in‑class NASH therapy, and the stock rallied on anticipation of a positive decision.

Pharmacokinetics / Pharmacodynamics (PK/PD)

Pharmacokinetics describes what the body does to a drug (absorption, distribution, metabolism, excretion), while pharmacodynamics describes what the drug does to the body (the relationship between concentration and effect). Together, PK/PD data help establish dosing regimens and are critical in phase I and II studies.

Example: In the development of Pfizer’s Paxlovid, pharmacokinetic boosting with ritonavir allowed the active nirmatrelvir to maintain plasma levels above the antiviral target for the 5‑day treatment course.

Pipeline

The collection of drug candidates a company is developing, often visualized as a chart showing the stage of each program from discovery through registration. Investors evaluate a pipeline’s depth (number of assets), breadth (number of therapeutic areas), and maturity (proportion in late‑stage vs. early‑stage) to gauge future growth potential.

Example: Roche’s pipeline includes over 80 new molecular entities across oncology, neuroscience, ophthalmology, and immunology, with 20 in phase III or registration.

Priority Review

A designation granted by the FDA to drugs that, if approved, would provide a significant improvement in safety or effectiveness compared to standard applications. Priority Review shortens the review timeline from ten months to six months, accelerating time to market.

Example: GSK’s RSV vaccine Arexvy received Priority Review and was approved in May 2023, making it the first respiratory syncytial virus vaccine for older adults.

Regulatory Catalyst

A scheduled event — such as an FDA advisory committee meeting, a PDUFA date, an EMA CHMP opinion, or the acceptance of an NDA — that could materially change a biotech’s valuation. Catalysts are often the primary focus for event‑driven investors who seek to capitalize on binary outcomes.

Example: The FDA’s advisory committee vote on the efficacy of Biogen’s Aduhelm in November 2020 was a major regulatory catalyst that sent shares soaring 44% in a single session.

Royalty Financing

A funding arrangement where an investor provides capital to a biotech company in exchange for a percentage of future revenue from a specific product, usually after it is approved. This dilutive‑free structure is attractive to companies that want to retain equity, but it commits a portion of future profits.

Example: BridgeBio raised $750 million in 2023 through a royalty deal on sales of its heart drug acoramidis, helping fund commercial launch expenses without issuing new shares.

Small Molecule Drug

A low‑molecular‑weight organic compound (typically less than 900 daltons) that can be administered orally and easily cross cell membranes. Small molecules are chemically synthesized and often have a lower cost of goods than biologics. They form the backbone of traditional pharmaceutical portfolios.

Example: Merck’s Januvia (sitagliptin) is a small‑molecule DPP‑4 inhibitor taken once daily for type 2 diabetes, generating over $3 billion in annual sales before patent expiry.

Therapeutic Window

The range of drug doses that produce a therapeutic effect without causing unacceptable toxicity. A wide therapeutic window indicates a large safety margin, while a narrow window requires careful monitoring. Drugs with a narrow window are often subject to therapeutic drug monitoring (TDM).

Example: The anticoagulant warfarin has a notoriously narrow therapeutic window, requiring frequent blood tests to avoid bleeding or clotting complications.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.